Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule

The clinical efficacy of antiangiogenic small molecules (e.g., sunitinib) in breast carcinoma has largely failed with substantial off-target toxicity. We rationally designed and evaluated preclinically a novel sunitinib analogue, SAP, with favourable pharmacological properties and the ability to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Argyros, Orestis, Karampelas, Theodoros, Varela, Aimilia, Asvos, Xenophon, Papakyriakou, Athanasios, Agalou, Adamantia, Beis, Dimitris, Davos, Constantinos H., Fokas, Demosthenes, Tamvakopoulos, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514907/
https://www.ncbi.nlm.nih.gov/pubmed/28422745
http://dx.doi.org/10.18632/oncotarget.16763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514907/
https://www.ncbi.nlm.nih.gov/pubmed/28422745
http://dx.doi.org/10.18632/oncotarget.16763

Ejemplares similares